MPLT (MapLight Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)


MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $37.11
! 4 Warning Signs
View Full Analysis

What is MapLight Therapeutics Net Margin %?

MapLight Therapeutics MPLT +3.09% 14 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 941 Biotechnology companies, MapLight Therapeutics ranks worse than 106269.82% on this metric.

Net margin is calculated as Net Income divided by its Revenue. MapLight Therapeutics's Net Income for the three months ended in Mar. 2026 was $-60.67 Mil. MapLight Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, MapLight Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for MapLight Therapeutics's Net Margin % or its related term are showing as below:


MPLT's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.3
* Ranked among companies with meaningful Net Margin % only.

MapLight Therapeutics  (NAS:MPLT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

MapLight Therapeutics Net Margin % Related Terms

MapLight Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for MapLight Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics Net Margin % Chart

MapLight Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 0.00 0.00

MapLight Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MPLT vs COAG, CAPR, NVAX: Net Margin % Comparison

For the Biotechnology subindustry, MapLight Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MapLight Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where MapLight Therapeutics's Net Margin % falls into.


MPLT
14GF Score
MapLight Therapeutics Inc MPLT
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

MapLight Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-161.152/0
= %

MapLight Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-60.668/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
MapLight Therapeutics (MPLT) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on MapLight Therapeutics and its competitors. According to the industry distribution chart, MapLight Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry.
Is MapLight Therapeutics' Net Margin % too high?
MapLight Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, MapLight Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Net Margin % compare to COAG and CAPR?
According to the Biotechnology industry distribution chart, MapLight Therapeutics ranks #999999 out of 941 companies for Net Margin %. This places MapLight Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on MapLight Therapeutics and its competitors. MapLight Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.11
Price